5 November 2002
Cannabis trial results are 'encouraging', says Society
The Multiple Sclerosis Society has commented on the announcement by GW Pharmaceuticals plc of results from its first four completed Phase III clinical trials of cannabis-based treatments.
These preliminary trial results appear very encouraging and we look forward to seeing the full results reviewed, said the Society.
We hope we are moving much closer to the day when people with MS will have access to cannabis-derived drugs which have been proved both effective and safe in the treatment of symptoms of this long-term condition.
In the meantime, we continue to argue that people should not be criminalised for using a drug which can alleviate those often painful symptoms and have asked the police and prosecuting authorities to deal with cases sympathetically.